This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
After Golden Cross, Oatly Group AB Sponsored ADR (OTLY)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
OTLYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
OPK Raises $125 Million Against Royalties: What Investors Should Know
by Urbi Guha
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
OPKNegative Net Change PFENegative Net Change LLYNegative Net Change
medical medical-devices
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
by Urbi Guha
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
OPKNegative Net Change REGNNegative Net Change PFENegative Net Change
medical medical-devices
Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific
by Zacks Equity Research
ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.
ISRGPositive Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
by Urbi Guha
OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
OPKNegative Net Change PFENegative Net Change LHNegative Net Change
medical medical-devices
HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?
by Zacks Equity Research
Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.
HNGENegative Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
SNN Advances Surgical Robotics Through Imperial College Partnership
by Zacks Equity Research
Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.
SNNNegative Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
by Moumi Mondal
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
IARTPositive Net Change MDTPositive Net Change SYKPositive Net Change
medical medical-devices
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
by Moumi Mondal
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
HSICNegative Net Change MCKPositive Net Change XRAYPositive Net Change
medical medical-devices
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
by Zacks Equity Research
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
GKOSNegative Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices